BioMimetic Therapeutics, Inc. (BMTI) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q3 EPS of ($0.25), $0.06 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $428 million versus the consensus estimate of $350 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- VNET Group (VNET) Misses Q2 EPS by 164c
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
